Eleven Biotherapeutics reports Q1 EPS (11c) vs. (25c) in same quarter last year
Reports cash and cash equivalents were $19.7M as of March 31, compared to $20.3M for the same period in 2017. "2018 is set to be a transformational year for the company and, already in the first quarter, we have made important progress in advancing our lead program, Vicinium, for high-grade non-muscle invasive bladder cancer, or NMIBC," said Stephen Hurly, president and chief executive officer of Eleven Biotherapeutics. "Our Phase 3 registration trial, the VISTA Trial, investigating Vicinium for patients with high-grade NMIBC, is progressing well and recently completed enrollment. We look forward to presenting three-month data from the trial in an oral presentation at the American Urological Association Annual Meeting on May 21st, a significant catalyst for the company and our Vicinium program. High-grade NMIBC is a disease for which there is a desperate need for new treatment options, and we look forward to further exploring Vicinium as a potential treatment for these patients."